(S)-4-(4-((2-(3,5-diMethylphenyl)pyrrolidin-1-yl)Methyl)phenoxy)-3-fluorobenzaMide manufacturers
- LY-2456302
-
-
2026-06-30
- CAS:1174130-61-0
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 1000kg
- Aticaprant
-
- $1.00
-
2026-06-16
- CAS:1174130-61-0
- Min. Order: 1G
- Purity: 99%
- Supply Ability: 600G
- Aticaprant
-
- $34.00
-
2026-06-02
- CAS:1174130-61-0
- Purity: 99.90%
- Supply Ability: 10g
|
| | (S)-4-(4-((2-(3,5-diMethylphenyl)pyrrolidin-1-yl)Methyl)phenoxy)-3-fluorobenzaMide Basic information |
| Product Name: | (S)-4-(4-((2-(3,5-diMethylphenyl)pyrrolidin-1-yl)Methyl)phenoxy)-3-fluorobenzaMide | | Synonyms: | (S)-4-(4-((2-(3,5-diMethylphenyl)pyrrolidin-1-yl)Methyl)phenoxy)-3-fluorobenzaMide;LY2456302;LY 2456302;CERC501;CERC 501;CS-2732;CERC-501(LY-2456302,Aticaprant);Benzamide, 4-[4-[[(2S)-2-(3,5-dimethylphenyl)-1-pyrrolidinyl]methyl]phenoxy]-3-fluoro-;4-[4-[[(2S)-2-(3,5-Dimethylphenyl)-1-pyrrolidinyl]methyl]phenoxy]-3-fluorobenzamide;Aticaprant (CERC-501);CERC 501,inhibit,LY2456302,Opioid Receptor,Aticaprant,Inhibitor,CERC501,LY 2456302 | | CAS: | 1174130-61-0 | | MF: | C26H27FN2O2 | | MW: | 418.5 | | EINECS: | | | Product Categories: | | | Mol File: | 1174130-61-0.mol |  |
| | (S)-4-(4-((2-(3,5-diMethylphenyl)pyrrolidin-1-yl)Methyl)phenoxy)-3-fluorobenzaMide Chemical Properties |
| Boiling point | 519.2±50.0 °C(Predicted) | | density | 1.201±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 1 mg/ml; DMSO: 5 mg/ml; Ethanol: 3 mg/ml; PBS (pH 7.2): insol | | form | A solid | | pka | 15.61±0.50(Predicted) | | color | White to off-white | | InChIKey | ZHPMYDSXGRRERG-DEOSSOPVSA-N | | SMILES | C(N)(=O)C1=CC=C(OC2=CC=C(CN3CCC[C@H]3C3=CC(C)=CC(C)=C3)C=C2)C(F)=C1 |
| | (S)-4-(4-((2-(3,5-diMethylphenyl)pyrrolidin-1-yl)Methyl)phenoxy)-3-fluorobenzaMide Usage And Synthesis |
| Uses | Aticaprant is a κ-opioid receptor agonist which may be used in the treatment of neurological diseases and disorders such as Alzheimer''s disease. | | in vivo | Aticaprant (CERC-501) has a rapid absorption (tmax=1-2 h) and good oral bioavailability (F=25%). Oral Aticaprant (CERC-501) administration selectively and potently occupies central kappa opioid receptors (ED50=0.33 mg/kg), without evidence of mu or delta receptor occupancy. LY2456302 potently blocks kappa-agonist-mediated analgesia and disruption of prepulse inhibition, without affecting mu-agonist-mediated effects at doses >30-fold higher. Aticaprant (CERC-501) produces antidepressant-like effects in the mouse forced swim test and enhances the effects of imipramine and citalopram. Aticaprant (CERC-501) reduces ethanol self-administration in alcohol-preferring rats[1]. Aticaprant (CERC-501) alleviates the nicotine withdrawal syndrome, as evidenced by decreased expression of nicotine withdrawal induced anxiety-related behavior, somatic signs, and CPA, and increased hotplate latency in nicotine withdrawn mice following pre-treatment[2]. |
| | (S)-4-(4-((2-(3,5-diMethylphenyl)pyrrolidin-1-yl)Methyl)phenoxy)-3-fluorobenzaMide Preparation Products And Raw materials |
|